Reshape Lifesciences Inc (NASDAQ:RSLS) was the target of a large decrease in short interest in September. As of September 28th, there was short interest totalling 1,159,023 shares, a decrease of 49.3% from the September 14th total of 2,288,097 shares. Based on an average daily trading volume, of 6,670,116 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.4% of the shares of the company are short sold.
RSLS opened at $0.03 on Friday. The company has a market capitalization of $400,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.77. Reshape Lifesciences has a 1-year low of $0.03 and a 1-year high of $39.00.
Reshape Lifesciences (NASDAQ:RSLS) last released its earnings results on Tuesday, August 14th. The medical device company reported ($4.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.79) by ($3.01). The firm had revenue of $0.65 million during the quarter. Reshape Lifesciences had a negative return on equity of 70.96% and a negative net margin of 2,397.35%. Equities analysts predict that Reshape Lifesciences will post -2.64 EPS for the current fiscal year.
A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered Reshape Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. ValuEngine downgraded Reshape Lifesciences from a “buy” rating to a “hold” rating in a research report on Tuesday, October 2nd. Finally, LADENBURG THALM/SH SH downgraded Reshape Lifesciences from a “buy” rating to a “neutral” rating in a research report on Friday, August 3rd.
About Reshape Lifesciences
ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses.
Recommended Story: Buyback For Investors Defined
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.